These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10169388)

  • 1. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.
    Garattini L; Brunetti M; Salvioni F; Barosi M
    Pharmacoeconomics; 1997 Jul; 12(1):67-75. PubMed ID: 10169388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.
    Hendry BM; Viberti GC; Hummel S; Bagust A; Piercy J
    QJM; 1997 Apr; 90(4):277-82. PubMed ID: 9307762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
    Laffel LM; McGill JB; Gans DJ
    Am J Med; 1995 Nov; 99(5):497-504. PubMed ID: 7485207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach].
    Le Pen C; Petitjean P; Lévy P; Hannedouche T
    Nephrologie; 1996; 17(6):321-6. PubMed ID: 8975150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome.
    Hod M; van Dijk DJ; Karp M; Weintraub N; Rabinerson D; Bar J; Peled Y; Erman A; Boner G; Ovadia J
    Nephrol Dial Transplant; 1995 Dec; 10(12):2328-33. PubMed ID: 8808235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD; Sandoz MS; Keusch GW
    Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation.
    Kiberd BA; Jindal KK
    Am J Kidney Dis; 1998 Jan; 31(1):49-54. PubMed ID: 9428451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
    Parving HH; Hommel E; Jensen BR; Hansen HP
    Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE inhibitors in patients with diabetes mellitus. Clinical and economic considerations.
    Borch-Johnsen K
    Pharmacoeconomics; 1996 May; 9(5):392-8. PubMed ID: 10160252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
    Wilmer WA; Hebert LA; Lewis EJ; Rohde RD; Whittier F; Cattran D; Levey AS; Lewis JB; Spitalewitz S; Blumenthal S; Bain RP
    Am J Kidney Dis; 1999 Aug; 34(2):308-14. PubMed ID: 10430979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibition in diabetic patients. Economic implications.
    Rodby RA; Lewis EJ
    Pharmacoeconomics; 1996 Oct; 10(4):315-20. PubMed ID: 10163576
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.